While China has quickly developed its own vaccine and stepped up production, Chinese pharmaceutical companies are also seeking cooperation with foreign vaccine makers to provide communist virus vaccines to the world’s most populous country, Agence France-Presse reported.
BioNTech has been working with Pfizer inc. to develop a vaccine against the Chinese communist virus since March. At the same time with China Fosun pharmaceutical group also carried out strategic cooperation. The latter has been licensed to market BioNTech’s products commercially in China.
Shanghai Fosun Pharma Group said on Wednesday it had reached an agreement with Germany’s BioNTech to ensure “adequate supply” of vaccines in China. According to a statement released by Fosun Pharma, the advance payment for the first batch of 50 million doses of Chinese communist virus vaccine products under the supply agreement is 250 million euros, of which 125 million euros will be paid before December 30, 2020, and the balance will be paid after the products are approved for listing in the Chinese mainland.
According to Reuters, BioNTech has committed to supply China with no less than 100 million doses of its MRNV vaccine by 2021, subject to approval and other conditions being met.
Fosun’s Hong Kong shares rose more than 2 per cent to HK $36.95 in early trading on Wednesday. A-shares also rose more than 2 per cent.
BionTech is reportedly selling the Virus vaccine in the United States for 33 euros for two doses.
BioNTech of Germany and Pfizer of the United States have approved mRNA vaccines in the United States, Britain and Singapore, among other countries.
MRNA vaccines trigger an immune response by introducing mrnas that encode disease-specific antigens and using the protein-making mechanisms of host cells to produce antigens. In the human body, the production of these foreign antigens prepares the immune system to recognize and remember the viral antigens and protect against future viral infections caused by the same antigens.
Five of China’s vaccines are in the final stages of development. At least one million people are thought to have been vaccinated with a candidate vaccine after it was approved for emergency use.